Merck

Yahoo Finance • 2 days ago

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower... Full story

Yahoo Finance • 3 days ago

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep Limited Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the futility analysis Over 100 clinical sites across 24 countries now acti... Full story

Yahoo Finance • 3 days ago

Next CDC AdCom meeting on vaccines delayed

[Centers for disease control and prevention sign] sshepard The Centers for Disease Control and Prevention (CDC) has postponed an October meeting of its Advisory Committee on Immunization Practices (ACIP), an expert panel whose views are c... Full story

Yahoo Finance • 3 days ago

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

RAHWAY, N.J., October 09, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European... Full story

Yahoo Finance • 3 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

Company Logo The bispecific antibodies market presents key opportunities in oncology, autoimmune, and infectious diseases, driven by rapid technological advancements and strategic collaborations. Regional manufacturing and diverse supplie... Full story

Yahoo Finance • 4 days ago

MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Merck between February 3, 2022, t... Full story

Yahoo Finance • 4 days ago

Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest.Verona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA);... Full story

Yahoo Finance • 4 days ago

Chart Expert Says Merck (MRK) Has More Upside – Here’s Why

We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks. Carter Worth from Worth Charting said in a latest program... Full story

Yahoo Finance • 4 days ago

Transjovan Capital participates at the 69th Annual General Meeting of the Indo-German Chamber of Commerce

MUMBAI, India, Oct. 8, 2025 /PRNewswire/ -- The Indo-German Chamber of Commerce hosted its 69th Annual General Meeting on 24th September 2025 in Mumbai. As a member firm, Transjovan Capital's Managing Partner, Gaurav Asthana attended the a... Full story

Yahoo Finance • 4 days ago

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

Company Logo The global cutaneous squamous cell carcinoma market is set for robust growth, driven by rising skin cancer incidences and treatment advancements. This market expansion is fueled by increased UV exposure, environmental factors... Full story

Yahoo Finance • 4 days ago

Merck (MRK): Assessing Valuation Following Recent Month’s Modest Share Price Increase

Merck (MRK) has recently wrapped up another month of trading, sparking renewed discussion about its longer-term performance. Investors are evaluating the stock’s modest month climb and considering how it compares to the company’s broader t... Full story

Yahoo Finance • 4 days ago

Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations

Lab equipment scheduling platform supporting pharma and life sciences R&D organisations’ AI journey amidst industry upheaval LONDON, October 08, 2025--(BUSINESS WIRE)--Clustermarket, the lab equipment scheduling platform, has today announ... Full story

Yahoo Finance • 4 days ago

BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma

LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies... Full story

Yahoo Finance • 4 days ago

Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks

Merck & Co., Inc. (NYSE:MRK) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now.Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks An American multinational pharmaceutical company, Merc... Full story

Yahoo Finance • 5 days ago

Energy Robotics Secures $13.5 Million Series A to Scale Critical Infrastructure Inspections with AI + Robotics

Company's leading hardware-agnostic fleet orchestration software platform delivers operational savings and worker safety to its customers DARMSTADT, Germany, Oct. 7, 2025 /PRNewswire/ -- Energy Robotics, the leading AI software platform f... Full story

Yahoo Finance • 6 days ago

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Verona Pharma plc LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on Ju... Full story

Yahoo Finance • 6 days ago

Assessing Merck Shares After Research Center Cuts and 13.5% Weekly Price Surge

Trying to decide what to do with Merck’s stock right now? You are definitely not alone. After all, just in the past week, Merck’s shares have jumped 13.5%, a rapid turnaround when you consider the stock is still down 10.1% for the year and... Full story

Yahoo Finance • 7 days ago

SA Asks: What's the most attractive Big Pharma stock right now?

[Pfizer HQ in New York City] georgeclerk What's the most attractive Big Pharma stock right now? We asked Seeking Alpha analysts The Value Portfolio [https://seekingalpha.com/author/the-value-portfolio] and ALLKA Research [https://seeking... Full story

Yahoo Finance • 7 days ago

Bernstein Maintains a Hold Rating on Merck & Co (MRK)

Merck & Co., Inc. (NYSE:MRK) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Courtney Breen from Bernstein reiterated a Hold rating on Merck & Co., Inc. (NYSE:MRK) without disclosing any price target. Merck & Co., I... Full story

Yahoo Finance • 8 days ago

Jim Cramer on Danaher: “It Has Been a Huge Disappointment”

Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer put under the microscope. Cramer discussed it while highlighting the performance of healthcare stocks. He said: “Some of these healthcare stocks seem played out already to you... Full story